The acquisition of TCR changes significantly the balance of their business model and introduces uncertainty. Having said that, they bought TCR at a substantial discount to value. If they can strenghten TCR's operating performance (a big question) the acquisition could be a significant enhancement to CLP's balance sheet and the value of CLP stock. To me, that's the dilemma. I'm going to hold on for a while and see what happens.